YPEG-Somatropin is under clinical development by Xiamen Amoytop Biotech and currently in Phase II for Born Small For Gestational Age (SGA). According to GlobalData, Phase II drugs for Born Small For Gestational Age (SGA) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YPEG-Somatropin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YPEG-Somatropin overview
YPEG-somatropin is under development for the treatment of growth hormone deficiency (GHD), born small for gestational age, turner syndrome, idiopathic short stature. The therapeutic candidate is administered through subcutaneous route. It is a pegylated long-acting recombinant human growth hormone developed based on Y-shaped PEGylation modification technique which enables attachment of the linker to the therapeutic moiety with PEG through covalent bond. The therapeutic candidate targets somatropin receptor.
Xiamen Amoytop Biotech overview
Xiamen Amoytop Biotech is an biopharmaceutical company that manufactures, develops and markets recombinant pegylated protein drugs. The company’s product portfolio includes peginterferon Alfa-2b, Molgramostim, filgrastim, oprelvekin and reagents. Its pipeline products include ACT50, which treats Tumors and Neo-Angiogenesis and other related diseases; ACT60 for Immune Diseases; Pegfilgrastim, which targets neutropenia induced by cancer chemotherapy; PEG-EPO, which treats anemia caused by chronic kidney disease and PEG-Somatropin for hormone deficiency in pediatric patients. Xiamen Amoytop Biotech is headquartered in Xiamen, Fujian, China.
For a complete picture of YPEG-Somatropin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
